News & Events

Learn about what's new with CMC Biologics

AGC Inc. Decides to Launch Voluntary Tender Offer for Shares of Molmed

News

Tokyo, March 17, 2020 – AGC Inc., (Headquarters: Tokyo; President & CEO: Takuya Shimamura) has decided to launch a voluntary tender offer (“VTO”) to acquire all ordinary shares of Molecular Medicine S.p.A. (“Molmed”) a company with shares listed on the Italian Stock Exchange (Milan) pursuant to article 102, first paragraph, of the Italy Legislative Decree No. 58 of 24 February 1998 and related regulations. Molmed is a clinical stage biotechnology company focused on research, development, manufacturing and clinical validation of gene & cell therapies, and offers GMP services for the development and manufacturing of gene & cell therapies for third parties and/or in partnership at its authorized facilities (“CDMO Services”*1).

AGC Biologics Plasmid Production

News

 

Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseases

News

AGC Biologics Expands Plasmid DNA Offering

News

SEATTLE, December 11, 2019-- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from its Heidelberg site in Germany. With the demand for pDNA growing rapidly, AGC Biologics is leveraging 25 years of experience and comprehensive in-house analytics development to ensure customers short and dependable timelines.

BIO Japan October 14 - 16, 2020 in Yokohama, Japan

Events

We hope to see you at BIO Japan in Yokohama, Japan on October 14 - 16, 2020.

Bio Japan

CPhI Worldwide, October 13 - 15, 2020 in Milan, Italy

Events

We're looking forward to attending CPhI in Milan, Italy.  

Will you be joining us there? Let us know if you'd like to meet. Email us at info@agcbio.com

AGC Biologics’ $18m Investment in Seattle and Denmark Facilities Strengthens Global Footprint

News

SEATTLE, WA -- November 11th, 2019 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their development and manufacturing capabilities at their Seattle, Washington and Copenhagen, Denmark facilities will be expanded, as part of an ongoing commitment to deliver the highest standard of service for their customers.

AGC Biologics Appoints New Site Head/General Manager  of Copenhagen, Denmark Operations

News

Jeffrey D. Mowery Named Site Head/General Manager

AGC Biologics Appoints New Site Head/General Manager  of Chiba, Japan Operations

News

Naofumi Kagami Named Site Head/General Manager

AGC Biologics Appoints New Chief Technical Officer

News

Kasper Møller named Chief Technical Officer

Follow Us
Join us on LinkedIn Follow us on Twitter